Cargando…

A distinct repertoire of cancer‐associated fibroblasts is enriched in cribriform prostate cancer

Outcomes for men with localized prostate cancer vary widely, with some men effectively managed without treatment on active surveillance, while other men rapidly progress to metastatic disease despite curative‐intent therapies. One of the strongest prognostic indicators of outcome is grade groups bas...

Descripción completa

Detalles Bibliográficos
Autores principales: Hesterberg, Amanda B, Rios, Brenda L, Wolf, Elysa M, Tubbs, Colby, Wong, Hong Yuen, Schaffer, Kerry R, Lotan, Tamara L, Giannico, Giovanna A, Gordetsky, Jennifer B, Hurley, Paula J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073007/
https://www.ncbi.nlm.nih.gov/pubmed/33600062
http://dx.doi.org/10.1002/cjp2.205
_version_ 1783684034379907072
author Hesterberg, Amanda B
Rios, Brenda L
Wolf, Elysa M
Tubbs, Colby
Wong, Hong Yuen
Schaffer, Kerry R
Lotan, Tamara L
Giannico, Giovanna A
Gordetsky, Jennifer B
Hurley, Paula J
author_facet Hesterberg, Amanda B
Rios, Brenda L
Wolf, Elysa M
Tubbs, Colby
Wong, Hong Yuen
Schaffer, Kerry R
Lotan, Tamara L
Giannico, Giovanna A
Gordetsky, Jennifer B
Hurley, Paula J
author_sort Hesterberg, Amanda B
collection PubMed
description Outcomes for men with localized prostate cancer vary widely, with some men effectively managed without treatment on active surveillance, while other men rapidly progress to metastatic disease despite curative‐intent therapies. One of the strongest prognostic indicators of outcome is grade groups based on the Gleason grading system. Gleason grade 4 prostate cancer with cribriform morphology is associated with adverse outcomes and can be utilized clinically to improve risk stratification. The underpinnings of disease aggressiveness associated with cribriform architecture are not fully understood. Most studies have focused on genetic and molecular alterations in cribriform tumor cells; however, less is known about the tumor microenvironment in cribriform prostate cancer. Cancer‐associated fibroblasts (CAFs) are a heterogeneous population of fibroblasts in the tumor microenvironment that impact cancer aggressiveness. The overall goal of this study was to determine if cribriform prostate cancers are associated with a unique repertoire of CAFs. Radical prostatectomy whole‐tissue sections were analyzed for the expression of fibroblast markers (ASPN in combination with FAP, THY1, ENG, NT5E, TNC, and PDGFRβ) in stroma adjacent to benign glands and in Gleason grade 3, Gleason grade 4 cribriform, and Gleason grade 4 noncribriform prostate cancer by RNAscope®. Halo® Software was used to quantify percent positive stromal cells and expression per positive cell. The fibroblast subtypes enriched in prostate cancer were highly heterogeneous. Both overlapping and distinct populations of low abundant fibroblast subtypes in benign prostate stroma were enriched in Gleason grade 4 prostate cancer with cribriform morphology compared to Gleason grade 4 prostate cancer with noncribriform morphology and Gleason grade 3 prostate cancer. In addition, gene expression was distinctly altered in CAF subtypes adjacent to cribriform prostate cancer. Overall, these studies suggest that cribriform prostate cancer has a unique tumor microenvironment that may distinguish it from other Gleason grade 4 morphologies and lower Gleason grades.
format Online
Article
Text
id pubmed-8073007
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-80730072021-04-29 A distinct repertoire of cancer‐associated fibroblasts is enriched in cribriform prostate cancer Hesterberg, Amanda B Rios, Brenda L Wolf, Elysa M Tubbs, Colby Wong, Hong Yuen Schaffer, Kerry R Lotan, Tamara L Giannico, Giovanna A Gordetsky, Jennifer B Hurley, Paula J J Pathol Clin Res Original Articles Outcomes for men with localized prostate cancer vary widely, with some men effectively managed without treatment on active surveillance, while other men rapidly progress to metastatic disease despite curative‐intent therapies. One of the strongest prognostic indicators of outcome is grade groups based on the Gleason grading system. Gleason grade 4 prostate cancer with cribriform morphology is associated with adverse outcomes and can be utilized clinically to improve risk stratification. The underpinnings of disease aggressiveness associated with cribriform architecture are not fully understood. Most studies have focused on genetic and molecular alterations in cribriform tumor cells; however, less is known about the tumor microenvironment in cribriform prostate cancer. Cancer‐associated fibroblasts (CAFs) are a heterogeneous population of fibroblasts in the tumor microenvironment that impact cancer aggressiveness. The overall goal of this study was to determine if cribriform prostate cancers are associated with a unique repertoire of CAFs. Radical prostatectomy whole‐tissue sections were analyzed for the expression of fibroblast markers (ASPN in combination with FAP, THY1, ENG, NT5E, TNC, and PDGFRβ) in stroma adjacent to benign glands and in Gleason grade 3, Gleason grade 4 cribriform, and Gleason grade 4 noncribriform prostate cancer by RNAscope®. Halo® Software was used to quantify percent positive stromal cells and expression per positive cell. The fibroblast subtypes enriched in prostate cancer were highly heterogeneous. Both overlapping and distinct populations of low abundant fibroblast subtypes in benign prostate stroma were enriched in Gleason grade 4 prostate cancer with cribriform morphology compared to Gleason grade 4 prostate cancer with noncribriform morphology and Gleason grade 3 prostate cancer. In addition, gene expression was distinctly altered in CAF subtypes adjacent to cribriform prostate cancer. Overall, these studies suggest that cribriform prostate cancer has a unique tumor microenvironment that may distinguish it from other Gleason grade 4 morphologies and lower Gleason grades. John Wiley & Sons, Inc. 2021-02-18 /pmc/articles/PMC8073007/ /pubmed/33600062 http://dx.doi.org/10.1002/cjp2.205 Text en © 2021 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland & John Wiley & Sons, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Hesterberg, Amanda B
Rios, Brenda L
Wolf, Elysa M
Tubbs, Colby
Wong, Hong Yuen
Schaffer, Kerry R
Lotan, Tamara L
Giannico, Giovanna A
Gordetsky, Jennifer B
Hurley, Paula J
A distinct repertoire of cancer‐associated fibroblasts is enriched in cribriform prostate cancer
title A distinct repertoire of cancer‐associated fibroblasts is enriched in cribriform prostate cancer
title_full A distinct repertoire of cancer‐associated fibroblasts is enriched in cribriform prostate cancer
title_fullStr A distinct repertoire of cancer‐associated fibroblasts is enriched in cribriform prostate cancer
title_full_unstemmed A distinct repertoire of cancer‐associated fibroblasts is enriched in cribriform prostate cancer
title_short A distinct repertoire of cancer‐associated fibroblasts is enriched in cribriform prostate cancer
title_sort distinct repertoire of cancer‐associated fibroblasts is enriched in cribriform prostate cancer
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073007/
https://www.ncbi.nlm.nih.gov/pubmed/33600062
http://dx.doi.org/10.1002/cjp2.205
work_keys_str_mv AT hesterbergamandab adistinctrepertoireofcancerassociatedfibroblastsisenrichedincribriformprostatecancer
AT riosbrendal adistinctrepertoireofcancerassociatedfibroblastsisenrichedincribriformprostatecancer
AT wolfelysam adistinctrepertoireofcancerassociatedfibroblastsisenrichedincribriformprostatecancer
AT tubbscolby adistinctrepertoireofcancerassociatedfibroblastsisenrichedincribriformprostatecancer
AT wonghongyuen adistinctrepertoireofcancerassociatedfibroblastsisenrichedincribriformprostatecancer
AT schafferkerryr adistinctrepertoireofcancerassociatedfibroblastsisenrichedincribriformprostatecancer
AT lotantamaral adistinctrepertoireofcancerassociatedfibroblastsisenrichedincribriformprostatecancer
AT giannicogiovannaa adistinctrepertoireofcancerassociatedfibroblastsisenrichedincribriformprostatecancer
AT gordetskyjenniferb adistinctrepertoireofcancerassociatedfibroblastsisenrichedincribriformprostatecancer
AT hurleypaulaj adistinctrepertoireofcancerassociatedfibroblastsisenrichedincribriformprostatecancer
AT hesterbergamandab distinctrepertoireofcancerassociatedfibroblastsisenrichedincribriformprostatecancer
AT riosbrendal distinctrepertoireofcancerassociatedfibroblastsisenrichedincribriformprostatecancer
AT wolfelysam distinctrepertoireofcancerassociatedfibroblastsisenrichedincribriformprostatecancer
AT tubbscolby distinctrepertoireofcancerassociatedfibroblastsisenrichedincribriformprostatecancer
AT wonghongyuen distinctrepertoireofcancerassociatedfibroblastsisenrichedincribriformprostatecancer
AT schafferkerryr distinctrepertoireofcancerassociatedfibroblastsisenrichedincribriformprostatecancer
AT lotantamaral distinctrepertoireofcancerassociatedfibroblastsisenrichedincribriformprostatecancer
AT giannicogiovannaa distinctrepertoireofcancerassociatedfibroblastsisenrichedincribriformprostatecancer
AT gordetskyjenniferb distinctrepertoireofcancerassociatedfibroblastsisenrichedincribriformprostatecancer
AT hurleypaulaj distinctrepertoireofcancerassociatedfibroblastsisenrichedincribriformprostatecancer